InspireMD, Inc. (NSPR) shareholders
Close on Nov 17, 2026Market cap $30.22MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Marshall Wace, Llp | 28,103,699 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Aharon Gil Joint filing with Rosalind Advisors, Inc. (9.90%), Salamon Steven A J (9.90%) and 1 more | 10,987,104 | 9.90% | 13G (passive) amendment | Aug 1, 2025 |
| Rosalind Advisors, Inc. Joint filing with Salamon Steven A J (9.20%), Aharon Gil (9.20%) and 1 more | 10,987,104 | 9.20% | 13G (passive) amendment | Dec 31, 2025 |
| Salamon Steven A J Joint filing with Rosalind Advisors, Inc. (9.40%), Aharon Gil (9.40%) and 1 more | 10,987,104 | 9.40% | 13G (passive) amendment | Mar 31, 2025 |
| Daniel Mack Joint filing with Nantahala Capital Management, LLC (9.99%), Wilmot B. Harkey (9.99%) | 4,819,647 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Wilmot B. Harkey Joint filing with Nantahala Capital Management, LLC (9.99%), Daniel Mack (9.99%) | 4,255,729 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Michael A. Lawless | 3,614,731 | 8.60% | 13D (active) | Jun 26, 2025 |
| Aberdeen Group plc Joint filing with abrdn Inc. (7.49%) | 3,173,364 | 7.49% | 13G (passive) amendment | Dec 31, 2025 |
| Orbimed Advisors LLC Joint filing with OrbiMed Capital GP IX LLC (6.80%) | 3,133,405 | 7.40% | 13G (passive) | Dec 31, 2025 |
| Nantahala Capital Management, LLC Joint filing with Wilmot B. Harkey (9.99%), Daniel Mack (9.99%) | 3,037,935 | 9.99% | 13G (passive) amendment | Mar 31, 2025 |
| Marvin Slosman | 2,556,760 | 5.18% | 13D (active) | Jan 22, 2026 |
| Parkman Healthcare Partners LLC Joint filing with Parkman Healthcare Partners Holdings LP (5.80%), Parkman Healthcare Partners Holdings GP LLC (5.80%) and 1 more | 2,440,633 | 5.80% | 13G (passive) | Sep 30, 2025 |
| Nantahala Capital Partners Limited Partnership | 2,418,016 | 5.68% | 13G (passive) amendment | Sep 30, 2025 |
| Venkataraman Balaji Joint filing with Velan Capital Master Fund LP (5.10%), Velan Capital Holdings LLC (5.10%) and 3 more | 2,143,698 | 5.10% | 13G (passive) | Jul 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NSPR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 6,752,968 | 14.53% | $4.73M | +3,376,484 | 0.08% |
| Rosalind Advisors, Inc. | 3,905,743 | 8.40% | $2.73M | – | 1.02% |
| abrdn plc | 3,698,364 | 7.96% | $2.59M | +525,000 | 0.00% |
| Orbimed Advisors LLC | 3,133,405 | 6.74% | $2.19M | – | 0.04% |
| Parkman Healthcare Partners LLC | 2,416,518 | 5.20% | $1.69M | – | 0.17% |
| Marshall Wace, Llp | 1,860,405 | 4.00% | $1.30M | – | 0.00% |
| Soleus Capital Management, L.P. | 1,045,708 | 2.25% | $732.10K | – | 0.03% |
| Pura Vida Investments, LLC | 450,517 | 0.97% | $315.41K | – | 1.91% |
| Ingalls & Snyder LLC | 368,800 | 0.79% | $258.00K | −10,500 | 0.01% |
| Affiance Financial, LLC | 250,370 | 0.54% | $175.28K | – | 0.03% |
| Velan Capital Investment Management LP | 148,138 | 0.32% | $103.71K | −1,951,514 | 0.06% |
| BlackRock, Inc. | 122,993 | 0.26% | $86.11K | +42,544 | 0.00% |
| Renaissance Technologies LLC | 112,832 | 0.24% | $78.99K | +95,223 | 0.00% |
| Creative Planning | 108,964 | 0.23% | $76.29K | +89,250 | 0.00% |
| Schonfeld Strategic Advisors LLC | 99,275 | 0.21% | $69.50K | New | 0.00% |
| Hrt Financial LP | 59,754 | 0.13% | $41.00K | New | 0.00% |
| XTX Topco Ltd | 49,029 | 0.11% | $34.33K | +36,671 | 0.00% |
| Centiva Capital, LP | 44,123 | 0.09% | $30.89K | +19,357 | 0.00% |
| Cambridge Investment Research Advisors, Inc. | 40,332 | 0.09% | $28.00K | New | 0.00% |
| Millennium Management LLC | 37,677 | 0.08% | $26.38K | −74,746 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 37 | 25M | 53.6% | 7 / 11 | 5 / 5 | 4M | 2M |
| Q1 2026 | 35 | 23M | 49.0% | 3 / 4 | 10 / 12 | 0M | 0M |
| Q4 2025 | 45 | 23M | 49.8% | 12 / 7 | 6 / 8 | 2M | 2M |
| Q3 2025 | 41 | 23M | 48.9% | 10 / 15 | 3 / 5 | 9M | 1M |
| Q2 2025 | 36 | 14M | 30.3% | 9 / 9 | 0 / 8 | 1M | 0M |
| Q1 2025 | 35 | 13M | 27.8% | 7 / 4 | 5 / 1 | 1M | 1M |
| Q4 2024 | 30 | 13M | 27.3% | 4 / 5 | 3 / 2 | 1M | 1M |
| Q3 2024 | 28 | 12M | 26.7% | 5 / 2 | 5 / 1 | 0M | 2M |
| Q2 2024 | 24 | 14M | 30.1% | 1 / 3 | 3 / 4 | 4M | 0M |
| Q1 2024 | 27 | 10M | 22.2% | 2 / 3 | 4 / 3 | 0M | 2M |
| Q4 2023 | 28 | 12M | 26.8% | 6 / 7 | 1 / 3 | 4M | 0M |
| Q3 2023 | 25 | 9M | 18.8% | 5 / 5 | 1 / 2 | 1M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
3 funds held NSPR in Q2 2026, 81% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NSPR | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Micro-Cap ETF | 114,832 | 0.25% | $80.39K | 0.01% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 18,244 | 0.04% | $16.80K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 8,161 | 0.02% | $5.71K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Marvin Slosman | CEO and President, Director | 3,602,812 | 7.75% | Nov 17, 2026 |
| Michael A. Lawless | Chief Financial Officer | 807,080 | 1.74% | Nov 17, 2026 |
| Shane Thomas Gleason | Chief Commercial Officer | 1,053,882 | 2.27% | May 21, 2026 |
| Andrea Tommasoli | Chief Operating Officer | 954,389 | 2.05% | Jan 16, 2026 |
| Craig Shore | CFO and CAO | 1,112,460 | 2.39% | Jan 10, 2025 |
| Patrick Verta | EVP Clinical/Medical Affairs | 311,532 | 0.67% | Jan 10, 2025 |
| Gary S. Roubin | Director | 988,324 | 2.13% | Nov 17, 2026 |
| Michael Berman | Director | 674,503 | 1.45% | Nov 17, 2026 |
| Paul Stuka | Director | 1,399,268 | 3.01% | Nov 17, 2026 |
| Scott R. Ward | Director | 237,096 | 0.51% | May 8, 2026 |
| Raymond W. Cohen | Director | 92,417 | 0.20% | Jan 16, 2026 |
| Danny L. Dearen | Director | 102,047 | 0.22% | Jan 16, 2026 |
| Kathryn Arnold | Director | 303,087 | 0.65% | Dec 31, 2025 |
| Thomas J. Kester | Director | 458,573 | 0.99% | Sep 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Paul Stuka Director | Nov 13, 2026 | Buy | +307,693 | $0.65 | $200.00K | 731,397 |
| Michael A. Lawless Chief Financial Officer | Nov 13, 2026 | Buy | +115,385 | $0.65 | $75.00K | 807,080 |
| Michael Berman Director | Nov 13, 2026 | Buy | +76,923 | $0.65 | $50.00K | 429,509 |
| Marvin Slosman CEO and President, Director | Nov 13, 2026 | Buy | +46,154 | $0.65 | $30.00K | 3,602,812 |
| Gary S. Roubin Director | Nov 13, 2026 | Buy | +153,846 | $0.65 | $100.00K | 988,324 |
| Paul Stuka Director | May 27, 2026 | Buy | +20,000 | $0.88 | $17.60K | 667,871 |
| Shane Thomas Gleason Chief Commercial Officer | May 19, 2026 | Sale | −22,778 | $1.01 | $23.01K | 1,053,882 |
| Paul Stuka Director | May 14, 2026 | Buy | +5,000 | $1.15 | $5.75K | 647,871 |
| Paul Stuka Director | May 13, 2026 | Buy | +10,000 | $1.16 | $11.60K | 642,871 |
| Marvin Slosman CEO and President, Director | May 12, 2026 | Buy | +21,000 | $1.20 | $25.20K | 3,556,658 |
| Paul Stuka Director | May 11, 2026 | Buy | +10,000 | $1.19 | $11.90K | 632,871 |
| Paul Stuka Director | May 11, 2026 | Buy | +10,000 | $1.19 | $11.90K | 632,871 |
| Paul Stuka Director | May 8, 2026 | Buy | +65,626 | $1.16 | $76.13K | 622,871 |
| Paul Stuka Director | May 8, 2026 | Buy | +65,626 | $1.16 | $76.13K | 622,871 |
| Gary S. Roubin Director | May 7, 2026 | Buy | +90,000 | $1.18 | $106.20K | 834,478 |
| Paul Stuka Director | May 7, 2026 | Buy | +6,378 | $1.15 | $7.33K | 531,599 |
| Scott R. Ward Director | May 7, 2026 | Buy | +73,255 | $1.15 | $84.24K | 237,096 |
| Paul Stuka Director | May 6, 2026 | Buy | +1,517 | $1.12 | $1.70K | 525,221 |
| Scott R. Ward Director | May 6, 2026 | Buy | +15,995 | $1.15 | $18.39K | 163,841 |
| Shane Thomas Gleason Chief Commercial Officer | Feb 2, 2026 | Sale | −2,941 | $1.59 | $4.68K | 1,076,660 |
| Shane Thomas Gleason Chief Commercial Officer | Feb 2, 2026 | Sale | −2,000 | $1.60 | $3.20K | 1,139,177 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 30, 2026 | Sale | −2,900 | $1.63 | $4.73K | 1,141,177 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 29, 2026 | Sale | −5,000 | $1.65 | $8.25K | 1,144,077 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 28, 2026 | Sale | −12,395 | $1.65 | $20.45K | 1,149,077 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 27, 2026 | Sale | −4,781 | $1.66 | $7.94K | 1,161,472 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 22, 2026 | Sale | −8,411 | $1.57 | $13.21K | 1,166,253 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 21, 2026 | Sale | −17,593 | $1.62 | $28.50K | 1,174,664 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 20, 2026 | Sale | −2,955 | $1.59 | $4.70K | 1,192,257 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 16, 2026 | Sale | −2,250 | $1.61 | $3.62K | 1,195,212 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 15, 2026 | Sale | −2,909 | $1.58 | $4.60K | 1,197,462 |
| Raymond W. Cohen Director | Jan 14, 2026 | Award | +44,030 | – | – | 92,417 |
| Scott R. Ward Director | Jan 14, 2026 | Award | +88,053 | – | – | 147,846 |
| Paul Stuka Director | Jan 14, 2026 | Award | +132,076 | – | – | 523,704 |
| Marvin Slosman CEO and President, Director | Jan 14, 2026 | Award | +1,114,792 | – | – | 3,535,658 |
| Michael Berman Director | Jan 14, 2026 | Award | +88,053 | – | – | 352,586 |
| Gary S. Roubin Director | Jan 14, 2026 | Award | +88,053 | – | – | 744,478 |
| Andrea Tommasoli Chief Operating Officer | Jan 14, 2026 | Award | +226,695 | – | – | 954,389 |
| Michael A. Lawless Chief Financial Officer | Jan 14, 2026 | Award | +226,695 | – | – | 691,695 |
| Shane Thomas Gleason Chief Commercial Officer | Jan 14, 2026 | Award | +453,390 | – | – | 1,200,371 |
| Danny L. Dearen Director | Jan 14, 2026 | Award | +44,030 | – | – | 102,047 |
| Kathryn Arnold Director | Dec 30, 2025 | Award | +55,556 | – | – | 303,087 |
| Paul Stuka Director | Dec 9, 2025 | Buy | +2,710 | $1.81 | $4.91K | 391,628 |
| Paul Stuka Director | Dec 9, 2025 | Buy | +5,073 | $1.81 | $9.18K | 391,628 |
| Paul Stuka Director | Dec 5, 2025 | Buy | +5,073 | $1.86 | $9.44K | 388,918 |
| Paul Stuka Director | Dec 4, 2025 | Buy | +10,130 | $1.85 | $18.74K | 383,845 |
| Paul Stuka Director | Nov 12, 2025 | Buy | +13,431 | $1.62 | $21.76K | 373,715 |
| Gary S. Roubin Director | Oct 7, 2025 | Award | +48,000 | – | – | 656,425 |
| Thomas J. Kester Director | Sep 15, 2025 | Award | +37,815 | – | – | 458,573 |
| Marvin Slosman CEO and President, Director | Jul 30, 2025 | Buy | +10,330 | $2.42 | $25.00K | 2,420,866 |
| Paul Stuka Director | Jul 30, 2025 | Buy | +20,661 | $2.42 | $50.00K | 444,195 |
| Thomas J. Kester Director | Jul 30, 2025 | Buy | +30,991 | $2.42 | $75.00K | 420,758 |
| Gary S. Roubin Director | Jul 30, 2025 | Buy | +41,322 | $2.42 | $100.00K | 608,425 |
| Thomas J. Kester Director | Jul 11, 2025 | Option exercise | +30,624 | $1.38 | $42.26K | 389,767 |
| Paul Stuka Director | Jul 1, 2025 | Option exercise | +87,500 | $1.38 | $120.75K | 423,534 |
| Michael Berman Director | Jun 29, 2025 | Option exercise | +61,248 | $1.38 | $84.52K | 244,994 |
| Gary S. Roubin Director | Jun 25, 2025 | Option exercise | +30,624 | $1.38 | $42.26K | 567,103 |
| Shane Thomas Gleason Chief Commercial Officer | May 30, 2025 | Sale | −7,186 | $2.51 | $18.04K | 1,079,601 |
| Shane Thomas Gleason Chief Commercial Officer | May 29, 2025 | Sale | −3,760 | $2.51 | $9.44K | 1,086,787 |
| Shane Thomas Gleason Chief Commercial Officer | May 27, 2025 | Sale | −1,572 | $2.51 | $3.95K | 1,090,547 |
| Shane Thomas Gleason Chief Commercial Officer | May 23, 2025 | Sale | −2,482 | $2.51 | $6.23K | 1,092,119 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of InspireMD's stock actually held short. Settlement fails (shares not delivered on time) peaked at 9,377 shares on Sep 16, 2026 over the last 90 days.
See a number that looks wrong?